Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Lees, K.R.; Bath, P.M.W.; Schellinger, P.; Kerr, D.M.; Fulton, R.; Hacke, W.; Matchar, D.; Sehra, R.; Toni, D. (2012)
Publisher: American Stroke Association
Languages: English
Types: Article
BACKGROUND AND PURPOSE:\ud \ud The diversity of available outcome measures for acute stroke trials is challenging and implies that the scales may be imperfect. To assist researchers planning trials and to aid interpretation, this article reviews and makes recommendations on the available choices of scales. The aim is to identify an approach that will be universally accepted and that should be included in most acute trials, without seeking to restrict options for special circumstances.\ud METHODS:\ud \ud The article considers outcome measures that have been widely used or are currently advised. It examines desirable properties for outcome measures such as validity, relevance, responsiveness, statistical properties, availability of training, cultural and language issues, resistance to comorbidity, as well as potential weaknesses. Tracking and agreement among outcomes are covered.\ud RESULTS:\ud \ud Typical ranges of scores for the common scales are described, along with their statistical properties, which in turn influence optimal analytic techniques. The timing of recovery on scores and usual practice in trial design are considered.\ud CONCLUSIONS:\ud \ud The preferred outcome measure for acute trials is the modified Rankin Scale, assessed at 3 months after stroke onset or later. The interview should be conducted by a certified rater and should involve both the patient and any relevant caregiver. Incremental benefits at any level of the modified Rankin Scale may be acceptable. The modified Rankin Scale is imperfect but should be retained in its present form for comparability with existing treatment comparisons. No second measure should be required, but correlations with supporting scales may be used to confirm consistency in direction of effects on other measures.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Bath PM, Lees KR, Schellinger PD, Altman H, Bland M, Hogg C, et al, and for the European Stroke Organisation Outcomes Working Group; Statistical analysis of the primary outcome in acute stroke trials. Stroke. 2012;43:1171-1178.
    • 2. Lees KR, Bath PM, Schellinger PD, Kerr DM, Fulton R, Hacke W, et al, and for the European Stroke Organisation Outcomes Working Group. Contemporary outcome measures in acute stroke research: choice of primary outcome measure. Stroke. 2012;43:1163-1170.
    • 3. Tilley B, Marler J, Geller N, Lu M, Legler J, Brott T, et al. Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke tPA trial. Stroke. 1996;27: 2136-2142.
    • 4. Tilley BC, Huang P, O'Brien, PC. Global assessment variables. In: D'Agostino RB, Sullivan L, Massaro J, eds. Wiley Encyclopedia of Clinical Trials. New York: John Wiley & Sons, Inc; 2007.
    • 5. New PW, Buchbinder R. Critical appraisal and review of the Rankin Scale and its derivatives. Neuroepidemiology. 2006;26:4 -15.
    • 6. NINDS t-PS Stroke Study Group. Generalized efficacy of tPA for acute stroke: sub-group analyses of the NINDS tPA Stroke Trial. Stroke. 1997; 28:2119 -2125.
    • 7. O'Brien PC. Procedures for comparing samples with multiple endpoints. Biometrics. 1984;40:1079 -1087.
    • 8. Huang P, Goetz CG, Woolson R, Tilley BC, Kerr D, Palesch Y, et al. for The Parkinson Study Group. Using global statistical tests in long term Parkinson's disease clinical trials. Mov Disord. 2009;24:1732-1739.
    • 9. Marler JR, Tilley BC, Lu M, Brott TG, Lyden PC, Grotta JC, et al. for the NINDS rtPA Stroke Study Group. Early stroke treatment associated with better outcome. Neurology. 2000;55:1649 -1655.
    • 10. The ATLANTIS, ECASS, and NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rtPA stroke trials. Lancet. 2004;363: 768 -774.
    • 11. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al. for the ECASS, ATLANTIS, NINDS, and EPITHET rt-PA Study Group Investigators. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375:1695-1703.
    • 12. Rankin J. Cerebral vascular accidents in patients over the age of 60: II. Prognosis. Scot Med J. 1957;2:200 -215.
    • 13. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604 - 607.
    • 14. Candelise L, Pinardi G, Aritzu E, Musicco M. Telephone interview for stroke outcome assessment. Cerebrovasc Dis. 1994;4:341-343.
    • 15. Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, et al. Movement Disorder Society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord. 2007;22:41- 47.
  • No related research data.
  • No similar publications.

Share - Bookmark

Funded by projects

  • NIH | Parkinsons Disease Clinical...

Cite this article